DIPHERELINE 0.1 MG

Nchi: Israeli

Lugha: Kiingereza

Chanzo: Ministry of Health

Viambatanisho vya kazi:

TRIPTORELIN AS ACETATE

Inapatikana kutoka:

MEDISON PHARMA LTD

ATC kanuni:

L02AE04

Dawa fomu:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Tungo:

TRIPTORELIN AS ACETATE 0.1 MG/VIAL

Njia ya uendeshaji:

S.C

Dawa ya aina:

Required

Viwandani na:

IPSEN PHARMA, FRANCE

Kundi la matibabu:

TRIPTORELIN

Eneo la matibabu:

TRIPTORELIN

Matibabu dalili:

Female infertility: Management of ovarian stimulation in association with the gonadotrophins (hMG, FSH, hCG) in view of in vitro fertilisation and embrio transfer (I.V.F.E.T.) and other assisted conception techniques.

Idhini ya tarehe:

2011-01-31

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1.
TRADENAME OF THE MEDICINAL PRODUCT
DIPHERELINE 0.1 MG, POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
(S.C.).
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Composition of the powder
Triptorelin
...................................................................................
0.0001 g
:
Mannitol
......................................................................................
0.0100 g
For one dose
Composition of the solvent
Sodium chloride
...........................................................................
0.009 g
:
Water for injections q.s.
.............................................................. 1 ml
For one ampoule
3.
PHARMACEUTICAL FORM
Powder and solvent for solution for injection (S.C.)
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Female infertility: Management of ovarian stimulation in association
with the
gonadotrophins (hMG, FSH, hCG) in view of in vitro fertilisation and
embrio
transfer (I.V.F.E.T.) and other assisted conception techniques.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
PROSTATE CANCER
One daily injection of 0.1 mg triptorelin by subcutaneous route from
Day 1 to
Day 7, before changing to the prolonged release form.
FEMALE INFERTILITY
: in combination with gonadotrophins.
One daily subcutaneous injection from Day 2 of the menstrual cycle (at
the same time
as ovarian stimulation starts) until the day before the day set for
induction, i.e. an
average period of 10 to 12 days for each attempt.
4.3
CONTRA-INDICATIONS
Hypersensitivity to GnRH, its analogues or to one of the constituents.
4.4
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
PROSTATE CANCER
Warnings on beginning treatment
It has been reported that clinical symptoms (particularly bone pain)
may worsen on
beginning treatment but these cases are isolated and generally
transient. These
cases justify a careful medical supervision during the first few weeks
of treatment,
particularly in patients presenting with urinary tract obstruction and
in those with
vertebral metastases (se